Introduction
Granulocytic sarcoma (GS) or chloroma is an extramedullary tumor composed of immature myeloid cells. 1 The latter term derives from the Greek word wloró B (green), describing the typical green appearance of myeloblasts on myeloperoxidase staining. 2 GS was first used to describe an extramedullary solid destructive tumor mass composed of immature cells of the granulocytic series, 3 but was subsequently used to describe all forms of extramedullary myeloid leukemic infiltrates, the socalled extramedullary myeloid tumor. 4 GS most commonly presents concurrently with, or after, the diagnosis of chronic myeloproliferative disorders (MPD) or acute myelogenous leukemia (AML). It may also present without overt hematologic disease, that is, normal marrow and no history of AML or MPD. 5 Many of these cases are misdiagnosed as lymphoma. 6, 7 Patients with nonleukemic GS may eventually develop acute leukemia. 7, 8 Owing to the rarity of the disease, prospective studies to determine the best induction and maintenance therapy would be difficult in terms of patient accrual, and therefore therapeutic decisions are based on retrospective studies and case reports. We report on the incidence, presentation and the clinical outcome of patients with nonleukemic GS, who were treated mainly with chemotherapy and/or radiation therapy.
Patients and methods
The database of the Department of Pathology of the University of Texas, MD Anderson Cancer Center (MDACC) was searched for patients presenting with extramedullary myeloid diseases from January 1990 to June 2002. This database includes patients with chronic MPD, AML, and MDS. Also the database of the Department of Leukemia was searched for patients with GS, and all patients with AML or high-risk MDS, that is, refractory anemia with excess blasts (RAEB) or RAEB in transformation (RAEB-T), which presented at MDACC during the same time period. Patients were included in the study if they had biopsyproven extramedullary disease and no evidence of AML, RAEB, RAEB-T, chronic myelomonocytic leukemia, chronic myelogenous leukemia or other MPD in the bone marrow or the peripheral blood. All slides were reviewed at the MDACC to confirm the diagnosis.
All records were reviewed to investigate clinical and pathologic presentation, treatment and outcome. Patient evaluation included history, physical examination, complete blood count, platelet counts, and differential, biochemical profile, bone marrow aspirates and biopsies, cytogenetic analysis of bone marrow and available extramedullary tissue and available reports of chest X-ray and computerized tomography of head and neck, chest, abdomen and pelvis. Chromosomal analysis by conventional criteria was performed on bone marrow aspirates and/or available tissue at the time of diagnosis. 9 Treatment according to standard or investigational regimens was administered either at the MDACC. A signed informed consent was obtained before all therapy, in keeping with the policies of the MDACC.
Treatment
In all, 16 patients were treated with chemotherapy, three with chemotherapy and radiotherapy and one (with skin disease) radiotherapy only. One patient refused therapy. In all, 11 patients received idarubicin and ara-C (IA), two fludarabine. ara-C, idarubicin and G-CSF (FLAG); two cyclophosphamide. cytarabine, topotecan and G-CSF (CAT-G); one daunorubicin and ara-C. Three patients with central nervous system (n ¼ 2) or skin (n ¼ 1) disease received both radiation and chemotherapy.
End points and statistical methods
Complete remission (CR) was defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms. Partial remission (PR) was defined as a reduction by X50% of the sum of the products of the greatest diameters of bidimensionally measurable disease. Any other response was considered a failure. Survival was measured from the time of diagnosis until death from any cause, or last follow-up. Failure-free-survival (FFS) was defined as the time from time of diagnosis until relapse, progression to leukemia, death or last contact. The w 2 test was used to investigate the independence between two categorical variables. Survival curves were estimated using the Kaplan-Meier method. 10 Adverse events were evaluated using the National Cancer Institute common toxicity criteria (NCI-CTC).
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Results
Frequency
A total of 21 patients with nonleukemic GS were identified. The numbers of patients with AML and high-risk MDS are shown in Table 1 . GS occurred in 1.4% of patients with AML, and 1.1% of patients with AML or high-risk MDSs.
Pretreatment characteristics
The presenting clinical and laboratory characteristics of the patients with nonleukemic GS are listed in Table 2 . Median age was 57 years (range, 7-81). The median number of sites of involvement was 2 (range, 1-4). The most common extramedullary sites of involvement were skin, lymph nodes, testes, and central nervous system.
In total, 20 patients had cytogenetic analysis in the bone marrow (n ¼ 18) and/or extramedullary mass (n ¼ 4). Six patients (28%) had chromosome 8 abnormalities: trisomy 8 in the bone marrow (n ¼ 4); 8q -in the bone marrow and the lymph node (n ¼ 1); complex cytogenetic abnormalities including trisomy 8 and trisomy 7 in the bone marrow (n ¼ 1). One patient had inv (16) in the bone marrow; one patient had -7 and inv(2) in the bone marrow; one patient had deletion 12 in the lymph node; one patient with complex cytogenetics, including 11q -and 1 p -in the lymph node; and one patient had dup(1) and deletion 3 in the paraspinal mass and normal cytogenetics in the bone marrow. Nine patients (45%) had normal cytogenetics.
Response
Among the 20 patients, who received treatment and were evaluable for response, 13 patients (65%) achieved CR, one patient (5%) achieved PR and six patients failed to respond (early death, two patients; and refractory/progressive disease, four patients). Response according to treatment is shown in Table 3 . The median time to respond to chemotherapy was 28 days (range, 20-84). Three out of six patients (50%) with chromosome 8 abnormalities achieved CR compared with nine One patient was not treated because of poor performance status.
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who achieved CR (64%) and one with PR out of 14 patients with other cytogenetics (P ¼ 0.55).
Survival
The median follow-up of surviving patients is 12 months (range, 7-75). Among the 20 patients who received treatment, nine patients (45%) are still alive. Eight patients died from progressive disease, one patient from fever of unknown origin and heart failure, and two patients died from multiorgan failure, including one patient with sepsis. The patient who was not treated died 4 months after diagnosis from progressive disease. The median survival of patients treated with chemotherapy was 15 months and the projected 3-year survival was 30% with an apparent plateau after 2 years (Figure 1 ). In Figure 2 , the survival of patients with chromosome 8 abnormalities is compared with that of patients with other cytogenetics. Although survival was not significantly different between these two groups (P ¼ 0.17), five out of six patients (83%) with chromosome 8 abnormalities have died at the time of this writing (median survival of 12 months) compared with seven out of 14 patients with other cytogenetics (50%; median survival of 40 months).
Failure-free survival
A total of 12 patients have failed, including nine patients who died (Table 3) . Five patients developed AML with a median time to progression to AML of 5 months (range, 4-26); these patients were treated with chemotherapy group. Three patients died from progression of their GS. The projected 3-year FFS in patients who received chemotherapy was 21%.
Toxicity
Among the 20 patients who were treated with chemotherapy with or without radiotherapy, nine patients developed infections and/or sepsis (bacterial, six; fungal, one; viral, one; sepsis and pneumonia with negative cultures, one). There were six episodes of fever of unknown origin and two episodes of neutropenic fever. Six patients developed Grade 3-4 hemorrhagic episodes (gastrointestinal, two; subarachnoidal, one; hemorrhagic conjunctivitis, one; pulmonary hemorrhage, one; and vaginal, one). Other Grade 3-4 toxicities were as follows: arrhythmia, three patients; pulmonary edema, one patient; adult respiratory distress syndrome, one patient; hyperbilirubinemia, three patients; elevated serum creatinine, one patient, mucositis, one patient; diarrhea, one patient; and rash, one patient. Grade 1-2 toxicities were mainly electrolytic abnormalities, nausea, vomiting, and diarrhea.
Discussion
This is a retrospective analysis of nonleukemic GS patients, based on our referral population. In this population, the overall ratio of nonleukemic GS to AML and high-risk MDS is 0.011. The median age of patients with nonleukemic GS was similar to that of patients with AML and high-risk MDS in our institution. 12 Nonleukemic GS presented most frequently with skin lesions and lymphadenopathy. Chromosome 8 abnormalities were the dominant abnormalities in the bone marrow and/or extramedullary sites. In all, 13 patients achieved CR with chemotherapy, radiotherapy, or combined therapy, with a CR rate of 65%. The median FFS in all groups was 12 months and although the number of the patients is small, the overall survival was prolonged in patients treated with combined chemotherapy and radiotherapy (median, 40 months).
Our patient population was older (median age, 57) than that of a previous report on two new cases and 72 cases reviewed from the literature (median age, 33). 13 Skin, lymph nodes, breast, testis, and spleen were more frequently involved by GS in our study compared with previous reports, some of which are based on case reports. 13 In patients with nonleukemic GS, although CR rates are high, the FFS survival is short (Table 3 ). In the current study, among the five patients who progressed to AML, the median time to progression was 5 months (range, . This interval is comparable with a previous report from our institution on 16 patients who presented between 1962 and 1985; seven out of 14 patients with adequate follow-up progressed to AML, 1 week to 13 months after the diagnosis of nonleukemic GS. 7 Other investigators have reported a 10-12-month interval between the time of diagnosis and the time to Survival in patients with nonleukemic GS treated with chemotherapy.
Figure 2
Survival according to the presence or absence of chromosome 8 abnormality.
progression to AML. 13, 14 However, it is unclear whether this interval refers to the overall population with nonleukemic GS or patients who progressed to AML alone. 13 Interestingly, none of the three patients treated with chemotherapy combined with radiotherapy progressed to AML in the current study.
Previous studies support the use of intensive chemotherapy in patients with nonleukemic GS. Imrie et al 15 have reported that antileukemic chemotherapy at the time of diagnosis is associated with a significantly lower probability of developing AML and with prolonged survival. Stem cell transplantation has also been used as intensified postremission therapy in second CR. 15, 16 Patients with chromosome abnormalities appeared to have lower CR rates, shorter survival and FFS in our study. Although these differences did not reach statistical significance (Figure 3 ) -probably because of the small numbers of patients -an abnormal marrow karyotype may indicate a poor prognosis with GS and more intensive therapy may be required for these patients. This also leads one to consider if patients with a GS and an abnormal karyotype can be truly considered to have 'nonleukemic' disease -it is more likely that bone marrow cytogenetic analysis is a more sensitive test of marrow involvement. Extramedullary leukemia has been associated with poor prognosis in patients with AML and t(8;21). 17 Byrd et al 17 reported that among AML patients with t(8;21)(q22;q22) karyotype, those presenting with extramedullary leukemia have lower rates of CR and survival compared with those without extramedullary leukemia; and suggested that this finding is probably related to inadequate local therapy for patients with involvement of the central nervous system. The optimal therapy for patient with nonleukemic GS has not been determined. Our data indicate that AML-type intensive chemotherapy with or without radiotherapy was moderately effective. The addition of radiotherapy was associated with a prolonged FFS and should be considered, especially in patients with leukemia involvement of the central nervous system. Intensive therapy should be considered for patients with nonleukemic GS with chromosome 8 abnormalities. Novel approaches are required for patients with GS.
